Associations - BIRC3 mutation

BIOMARKER:

BIRC3 mutation

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

BIRC3 mutation BIRC3 mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	rituximab Resistant: C3 – Early Trials rituximab Resistant : C3
BIRC3 mutation BIRC3 mutation	Mantle Cell Lymphoma Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials temsirolimus Resistant : C3
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	FCR Resistant: C3 – Early Trials FCR Resistant : C3
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BR Resistant: C3 – Early Trials BR Resistant : C3
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	DC-1-192 Sensitive: D – Preclinical DC-1-192 Sensitive : D